Al-Ishaq RK, Abotaleb M, Kubatka P, et al., 2019. Flavonoids and their anti-diabetic effects: cellular mechanisms and effects to improve blood sugar levels. Biomolecules, 9(9):430. https://doi.org/10.3390/biom9090430https://doi.org/10.3390/biom9090430

Bhat AA, Yousuf P, Wani NA, et al., 2021. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy. Sig Transduct Target Ther, 6:12. https://doi.org/10.1038/s41392-020-00419-whttps://doi.org/10.1038/s41392-020-00419-w

Bhusal CK, Uti DE, Mukherjee D, et al., 2023. Unveiling Nature’s potential: promising natural compounds in Parkinson’s disease management. Parkinsonism Relat Disord, 115:105799. https://doi.org/10.1016/j.parkreldis.2023.105799https://doi.org/10.1016/j.parkreldis.2023.105799

Chen P, Zhang JY, Sha BB, et al., 2017. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget, 8(16):27471-27480. https://doi.org/10.18632/oncotarget.15832https://doi.org/10.18632/oncotarget.15832

Chen QM, Wang YH, Shuai J, 2023. Current status and future prospects of stomatology research. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 24(10):853-867. https://doi.org/10.1631/jzus.B2200702https://doi.org/10.1631/jzus.B2200702

Cook MT, 2018. Mechanism of metastasis suppression by luteolin in breast cancer. Breast Cancer (Dove Med Press), 10:89-100. https://doi.org/10.2147/BCTT.S144202https://doi.org/10.2147/BCTT.S144202

Davella R, Mamidala E, 2021. Luteolin: a potential multiple targeted drug effectively inhibits diabetes mellitus protein targets. J Pharm Res Int, 33(44B):161-171. https://doi.org/10.9734/jpri/2021/v33i44B32661https://doi.org/10.9734/jpri/2021/v33i44B32661

Fang J, Zhou Q, Shi XL, et al., 2007. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 28(3):713-723. https://doi.org/10.1093/carcin/bgl189https://doi.org/10.1093/carcin/bgl189

Fang XJ, Yu SX, Lu YL, et al., 2000. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci USA, 97(22):11960-11965. https://doi.org/10.1073/pnas.220413597https://doi.org/10.1073/pnas.220413597

Han T, Li HL, Zhang QY, et al., 2007. Bioactivity-guided fractionation for anti-inflammatory and analgesic properties and constituents of Xanthium strumarium L. Phytomedicine, 14(12):825-829. https://doi.org/10.1016/j.phymed.2007.01.010https://doi.org/10.1016/j.phymed.2007.01.010

He ZJ, Li XQ, Wang Z, et al., 2023. Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ-dependent mechanism in Alzheimer’s disease. Redox Biol, 66:102848. https://doi.org/10.1016/j.redox.2023.102848https://doi.org/10.1016/j.redox.2023.102848

Iida K, Naiki T, Naiki-Ito A, et al., 2020. Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway. Cancer Sci, 111(4):1165-1179. https://doi.org/10.1111/cas.14334https://doi.org/10.1111/cas.14334

Iliaki S, Beyaert R, Afonina IS, 2021. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem Pharmacol, 193:114747. https://doi.org/10.1016/j.bcp.2021.114747https://doi.org/10.1016/j.bcp.2021.114747

Imran M, Rauf A, Abu-Izneid T, et al., 2019. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed Pharmacother, 112:108612. https://doi.org/10.1016/j.biopha.2019.108612https://doi.org/10.1016/j.biopha.2019.108612

Jehn P, Dittmann J, Zimmerer R, et al., 2019. Survival rates according to tumour location in patients with surgically treated oral and oropharyngeal squamous cell carcinoma. Anticancer Res, 39(5):2527-2533. https://doi.org/10.21873/anticanres.13374https://doi.org/10.21873/anticanres.13374

Johnson DE, Burtness B, Leemans CR, et al., 2020. Head and neck squamous cell carcinoma. Nat Rev Dis Primers, 6:92. https://doi.org/10.1038/s41572-020-00224-3https://doi.org/10.1038/s41572-020-00224-3

Kang KA, Piao MJ, Ryu YS, et al., 2017. Luteolin induces apoptotic cell death via antioxidant activity in human colon cancer cells. Int J Oncol, 51(4):1169-1178. https://doi.org/10.3892/ijo.2017.4091https://doi.org/10.3892/ijo.2017.4091

Lakhera S, Rana M, Devlal K, et al., 2022. A comprehensive exploration of pharmacological properties, bioactivities and inhibitory potentiality of luteolin from Tridax procumbens as anticancer drug by in-silico approach. Struct Chem, 33(3):703-719. https://doi.org/10.1007/s11224-022-01882-7https://doi.org/10.1007/s11224-022-01882-7

Leemans CR, Snijders PJF, Brakenhoff RH, 2018. The molecular landscape of head and neck cancer. Nat Rev Cancer, 18(5):269-282. https://doi.org/10.1038/nrc.2018.11https://doi.org/10.1038/nrc.2018.11

Li QF, Tie Y, Alu A, et al., 2023. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Sig Transduct Target Ther, 8:31. https://doi.org/10.1038/s41392-022-01297-0https://doi.org/10.1038/s41392-022-01297-0

Liang GH, Zhao JL, Dou YX, et al., 2022. Mechanism and experimental verification of Luteolin for the treatment of osteoporosis based on network pharmacology. Front Endocrinol, 13:866641. https://doi.org/10.3389/fendo.2022.866641https://doi.org/10.3389/fendo.2022.866641

Lim W, Yang C, Bazer FW, et al., 2016. Luteolin inhibits proliferation and induces apoptosis of human placental choriocarcinoma cells by blocking the PI3K/AKT pathway and regulating sterol regulatory element binding protein activity. Biol Reprod, 95(4):82. https://doi.org/10.1095/biolreprod.116.141556https://doi.org/10.1095/biolreprod.116.141556

Lin D, Kuang G, Wan JY, et al., 2017. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Oncol Rep, 37(2):895-902. https://doi.org/10.3892/or.2016.5311https://doi.org/10.3892/or.2016.5311

Lin SC, Liu CJ, Chiu CP, et al., 2004. Establishment of OC3 oral carcinoma cell line and identification of NF‍-‍κB activation responses to areca nut extract. J Oral Pathol Med, 33(2):79-86. https://doi.org/10.1111/j.1600-0714.2004.00034.xhttps://doi.org/10.1111/j.1600-0714.2004.00034.x

Lin Y, Shi RX, Wang X, et al., 2008. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8(7):634-646. https://doi.org/10.2174/156800908786241050https://doi.org/10.2174/156800908786241050

Lopez-Lazaro M, 2009. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem, 9(1):31-59. https://doi.org/10.2174/138955709787001712https://doi.org/10.2174/138955709787001712

Mao YJ, Meng LK, Liu HY, et al., 2022. Therapeutic potential of traditional Chinese medicine for vascular endothelial growth factor. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(5):353-364. https://doi.org/10.1631/jzus.B2101055https://doi.org/10.1631/jzus.B2101055

Muruganathan N, Dhanapal AR, Baskar V, et al., 2022. Recent updates on source, biosynthesis, and therapeutic potential of natural flavonoid luteolin: a review. Metabolites, 12(11):1145. https://doi.org/10.3390/metabo12111145https://doi.org/10.3390/metabo12111145

Muzaffar J, Bari S, Kirtane K, et al., 2021. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers, 13(2):338. https://doi.org/10.3390/cancers13020338https://doi.org/10.3390/cancers13020338

Nabavi SF, Braidy N, Gortzi O, et al., 2015. Luteolin as an anti-inflammatory and neuroprotective agent: a brief review. Brain Res Bull, 119(Part A):1-11. https://doi.org/10.1016/j.brainresbull.2015.09.002https://doi.org/10.1016/j.brainresbull.2015.09.002

Naia L, Pinho CM, Dentoni G, et al., 2021. Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling. BMC Biol, 19:57. https://doi.org/10.1186/s12915-021-00979-5https://doi.org/10.1186/s12915-021-00979-5

Pandurangan AK, Dharmalingam P, Sadagopan SKA, et al., 2013. Luteolin induces growth arrest in colon cancer cells through involvement of Wnt/β-catenin/GSK-3β signaling. J Environ Pathol Toxicol Oncol, 32(2):131-139. https://doi.org/10.1615/jenvironpatholtoxicoloncol.2013007522https://doi.org/10.1615/jenvironpatholtoxicoloncol.2013007522

Potočnjak I, Šimić L, Gobin I, et al., 2020. Antitumor activity of luteolin in human colon cancer SW620 cells is mediated by the ERK/FOXO3a signaling pathway. Toxicol Vitro, 66:104852. https://doi.org/10.1016/j.tiv.2020.104852https://doi.org/10.1016/j.tiv.2020.104852

Pu YS, Zhang T, Wang JH, et al., 2018. Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs. J Cancer, 9(20):3669-3675. https://doi.org/10.7150/jca.27183https://doi.org/10.7150/jca.27183

Rehfeldt SCH, Silva J, Alves C, et al., 2022. Neuroprotective effect of luteolin-7-O-glucoside against 6-OHDA-induced damage in undifferentiated and RA-differentiated SH-SY5Y cells. Int J Mol Sci, 23(6):2914. https://doi.org/10.3390/ijms23062914https://doi.org/10.3390/ijms23062914

Reyes-Farias M, Carrasco-Pozo C, 2019. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. Int J Mol Sci, 20(13):3177. https://doi.org/10.3390/ijms20133177https://doi.org/10.3390/ijms20133177

Ruffin AT, Li H, Vujanovic L, et al., 2023. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer, 23(3):173-188. https://doi.org/10.1038/s41568-022-00531-9https://doi.org/10.1038/s41568-022-00531-9

Seelinger G, Merfort I, Wölfle U, et al., 2008a. Anti-carcinogenic effects of the flavonoid luteolin. Molecules, 13(10):2628-2651. https://doi.org/10.3390/molecules13102628https://doi.org/10.3390/molecules13102628

Seelinger G, Merfort I, Schempp CM, 2008b. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med, 74(14):1667-1677. https://doi.org/10.1055/s-0028-1088314https://doi.org/10.1055/s-0028-1088314

Sun BY, Liu YQ, He DH, et al., 2021. Traditional Chinese medicines and their active ingredients sensitize cancer cells to TRAIL-induced apoptosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(3):190-203. https://doi.org/10.1631/jzus.B2000497https://doi.org/10.1631/jzus.B2000497

Tuorkey MJ, 2016. Molecular targets of luteolin in cancer. Eur J Cancer Prev, 25(1):65-76. https://doi.org/10.1097/CEJ.0000000000000128https://doi.org/10.1097/CEJ.0000000000000128

Wang GG, Lu XH, Li W, et al., 2011. Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. Evid Based Complement Alternat Med, 2011:323171. https://doi.org/10.1155/2011/323171https://doi.org/10.1155/2011/323171

Wang HT, Yao XQ, Huang KL, et al., 2022. Low-dose dexamethasone in combination with luteolin improves myocardial infarction recovery by activating the antioxidative response. Biomed Pharmacother, 151:113121. https://doi.org/10.1016/j.biopha.2022.113121https://doi.org/10.1016/j.biopha.2022.113121

Zhang WB, Li DB, Shan Y, et al., 2023. Luteolin intake is negatively associated with all-cause and cardiac mortality among patients with type 2 diabetes mellitus. Diabetol Metab Syndr, 15:59. https://doi.org/10.1186/s13098-023-01026-9https://doi.org/10.1186/s13098-023-01026-9

Zhou Z, Chen J, Zhang ZX, et al., 2022. Solubilization of luteolin in PVP40 solid dispersion improves inflammation-induced insulin resistance in mice. Eur J Pharm Sci, 174:106188. https://doi.org/10.1016/j.ejps.2022.106188https://doi.org/10.1016/j.ejps.2022.106188